AMGN Amgen Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel ceiling · 12-month channel rising
Price is at the upper line, where it has stalled before.
- 12-month channel
- US$411.42 – US$472.78 · rising, +34% a year
- Price in channel
- 90% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$472.34
- Turns bearish below
- US$410.75
Price history, with the path projected 3 months forward
Updated 1:28 AM ET (9 h ago)
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$409.62
level as at 3 Nov 2026
Our target
US$471.06
by 2 Nov 2026
Projected move
15.0%
gross, before costs
Price is between our buy and target.
Target: AMGN's usual move size (15.0%), the best return per day on this path.
This move size: reached in 31% of 12 past stretches, typically in 89 days. (0.17% per day)
7 settled calls · 5 reached target (71.4%) · average best move 9.8%. See the full record.
- Upper line touches
- 3
- Lower line touches
- 4
- Fit confidence
- 72%
- Fitted
- 1 Nov 2026
Company information
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Bradway
- Employees
- 31,500
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$233.38B
- Enterprise value
- —
- Beta
- 0.41
- Avg volume
- 2.67M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 269.77-447.03
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.